Feature | May 20, 2015

CT-FFR Changes Treatment Plan for More Than One-Third of Coronary Artery Disease Patients

EuroPCR study uses HeartFlow Analysis software for non-invasive imaging of potential coronary artery disease

CT-FFR, Heartflow Analysis, coronary artery disease, EuroPCR, RIPCORD

May 20, 2015 — Adding the HeartFlow FFRCT Analysis to a standard coronary computed tomography angiogram (cCTA) may change the course of treatment in more than one-third of patients with coronary artery disease. This conclusion was discussed in a study presented at the EuroPCR 2015 conference. 

Results of the FFRCT RIPCORD study, presented by Prof. Nick Curzen of the University Hospital Southampton, United Kingdom, further reinforce the ability of the HeartFlow Analysis to aid in patient management.

The HeartFlow Analysis is a non-invasive imaging technology for coronary artery disease offering physicians insight on both the extent of any arterial blockage as well as whether it is impacting blood flow — two vital pieces of information physicians need to develop a treatment plan that is right for a patient. Using standard cCTA images, HeartFlow’s technology solves millions of complex equations simulating blood flow in the coronary arteries to provide mathematically computed fractional flow reserve (FFRCT) values.

In the study, three experienced cardiologists reviewed cCTAs of 200 consecutive cases of patients with stable chest pain. The physicians agreed upon a plan to manage each patient: optimal medical therapy, a percutaneous coronary intervention (PCI) such as a stent or coronary bypass surgery. In some cases, the physicians agreed that they were unable to make a decision and needed more information, such as an invasive diagnostic angiogram with associated invasive FFR. 

Next, the physicians were shown the results of the HeartFlow FFRCT Analysis for each case and made a second management decision incorporating these data. Adding the HeartFlow Analysis changed the decision to medical therapy in 26 of the 87 cases (30 percent) that were originally recommended for a PCI. Of cases originally recommended for medical therapy, 7 of 67 (9 percent) were changed to PCI and one was changed to bypass surgery. Without the HeartFlow Analysis, the physicians needed more information in 38 cases (19 percent), but with the HeartFlow Analysis, there were no cases in which the physicians needed additional information.

Overall, the management plan was changed in 72 of the 200 patients (36 percent). In 16 of the 87 cases considered candidates for PCI based on the angiogram (18 percent), one or more of the target lesions was changed using the FFRCT Analysis.

“It is well established that invasive FFR can refine management decisions based solely upon the angiogram for patients with chest pain,” said Curzen. “This study demonstrates that the non-invasive HeartFlow FFRCT Analysis has the potential to become the default method for the initial assessment of many patients with cardiac-sounding chest pain by assessing both the coronary anatomy and physiology simultaneously. This could have important implications for our clinical practice and would challenge conventional care pathways.” 

Invasive FFR is seen as the gold standard in diagnosing functionally significant coronary artery disease. In patients with multi-vessel disease, an FFR-directed PCI strategy is associated with better clinical outcomes compared to angiography-directed PCI (FAME; FAME 2). The FFRCT RIPCORD study was modeled after the original RIPCORD study, in which invasive FFR altered the course of patient management in 26 percent of cases when compared to angiographic assessment alone. 

For more information: www.heartflow.com

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init